Table 1.
Summary of PTMs identified and quantified for NIST mAb in the four different laboratories using peptide monitoring method and compliant CDS data processing
| Modification | Sequence | Relative abundance (n = 3) | |||
|---|---|---|---|---|---|
| Ireland | Denmark | UK | Switzerland | ||
| HC N328+Deam | VSNKALPAPIEK | 0.30 | 0.50 | 0.33 | 0.50 |
| CKVSNK | |||||
| VSNK | |||||
| HC N364+Deam | NQVSLTCLVK | 0.37 | 0.20 | 0.29 | 0.05 |
| EEMTKNQVSLTCLVK | |||||
| HC~N392/N387+Deam | GFYPSDIAVEWESNGQPENNYK | 0.79 | 0.21 | 0.24 | 0.64 |
| HC~N392/N387+Succ | GFYPSDIAVEWESNGQPENNYK | 2.06 | 2.27 | 2.73 | 2.60 |
| HC N318+Succ | VVSVLTVLHQDWLNGK | 2.05 | 2.61 | 2.66 | 2.25 |
| VVSVLTVLHQDWLNGKEYK | |||||
| HC D283+Succ | FNWYVDGVEVHNAK | 2.18 | 3.40 | 1.56 | 3.56 |
| TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK | |||||
| HC M255+Oxid | DTLMISR | 1.26 | 1.29 | 1.05 | 0.92 |
| HC K450 Lys loss | SLSLSPGK | 87.01 | 88.49 | 90.73 | 88.79 |
| WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK | |||||
| HC Q1+Gln->PyroGlu | QVTLR | 99.29 | 99.31 | 99.75 | 99.32 |
| HC N300+M5 | EEQYNSTYR | 1.71 | 1.29 | 1.10 | 1.22 |
| TKPREEQYNSTYR | |||||
| HC N300+A1G0F | EEQYNSTYR | 6.05 | 5.04 | 11.26 | 10.95 |
| TKPREEQYNSTYR | |||||
| HC N300+A2G0F | EEQYNSTYR | 41.13 | 40.14 | 37.36 | 37.05 |
| TKPREEQYNSTYR | |||||
| HC N300+A1G1F | EEQYNSTYR | 4.06 | 3.68 | 5.92 | 6.13 |
| TKPREEQYNSTYR | |||||
| HC N300+A2G1F | EEQYNSTYR | 36.11 | 38.65 | 33.86 | 34.89 |
| TKPREEQYNSTYR | |||||
| HC N300+A2G2F | EEQYNSTYR | 6.92 | 8.49 | 7.02 | 7.31 |
| TKPREEQYNSTYR | |||||
| HC N300+A2Ga1G1F | EEQYNSTYR | 0.91 | 1.42 | 1.09 | 1.21 |
| TKPREEQYNSTYR | |||||
| HC N300+unglycos | EEQYNSTYR | 3.06 | 1.29 | 2.39 | 1.25 |
| TKPREEQYNSTYR | |||||